ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0179

Social Disparities and Pathology Markers at Lupus Nephritis Diagnosis Predict Worse Kidney Outcomes

Shivani Garg1, Brad Astor2, Amish Raval2, S. Sam Lim3, Weixiong Zhong2, Sarah Panzer2, Brad Rovin4 and Christie M. Bartels2, 1Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 2University of Wisconsin, School of Medicine and Public Health, Madison, WI, 3Emory University, Atlanta, GA, 4Ohio State University, Columbus, OH

Meeting: ACR Convergence 2023

Keywords: Biomarkers, Disparities, Lupus nephritis, Outcome measures, socioeconomic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0176–0195) Healthcare Disparities in Rheumatology Poster I: Lupus

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: At diagnosis, a typical 30-year-old with lupus nephritis (LN) already has 10-fold higher chronic kidney disease (CKD) risk than peers and LN is a leading cause of end-stage kidney disease (ESKD) in young patients. Moreover, Black race is associated with a 6-fold higher risk of developing LN associated ESKD suggesting interactions between biological, socio-economic, and pathological factors can accelerate CKD progression and ESKD risk in LN. Examining early risk factors and interactions between socio-economic and biological factors can improve precision in identifying high-risk patients, yet these are under-examined in LN. Thus, we examined socio-economic and biological factors at LN diagnosis, and pathological markers in index kidney biopsies as predictors of CKD progression and ESKD among a longitudinal inception LN cohort.

Methods: Data including demographics, social factors, comorbidities, LN therapy, and pathology reports at LN diagnosis were abstracted from adult LN patients who underwent index kidney biopsy between 1994-2021. We abstracted LN chronicity and activity indices from index kidney biopsy slides and reports, and re-read biopsy slides to grade renal arteriosclerosis (ASCL) by calculating percent luminal narrowing. We measured two outcomes: a) time to CKD progression defined as a sustained decrease in eGFR ≥30% below the baseline, confirmed by ≥3 values for ≥ 3 months and progression to CKD stage ≥2 (eGFR < 90); b) time to ESKD with up to 12 years follow-up. Cox hazards models and Kaplan Meier (KM) survival analyses were used to examine whether socio-economic factors and pathology markers such as ASCL and activity and chronicity indices predict CKD progression and ESKD.

Results: Among 173 incident adult patients with LN, 75% were female and 35% were from Black and other racial groups. Mean age at LN diagnosis was 38±17 years, and 46% had public or no insurance. Mean renal ASCL (percent luminal narrowing), activity, and chronicity indices were 23%, 2.2, 1.9, respectively.

A total of 49 patients developed CKD progression over 12 years after LN diagnosis. KM survival curves highlighted accelerated CKD progression in patients with public or no insurance and LN chronicity index ≥5 (Fig. 1A). Patients with public or no insurance had 2-fold higher risk of CKD progression (Adjusted HR 2.2; Table 1). Increase in LN chronicity determined 40% higher CKD progression (Table 1).

Next, 19 patients developed ESKD. KM survival curves noted higher ESKD risk in patients with public or no insurance, severe renal ASCL, and LN chronicity index ≥5 at diagnosis (Fig. 1B). In a limited multivariable model, not including LN chronicity, severe renal ASCL was associated with 2.7 fold higher ESKD risk (Table 2). However, after including LN chronicity, only LN chronicity was associated with 40% higher ESKD risk (Table 2).

Conclusion: Socioeconomic barriers such as public or no insurance at diagnosis were the strongest, independent risk factor of CKD progression to stage ≥2. Additionally, higher LN chronicity in diagnostic biopsies was associated with greater ESKD risk. Future CKD prevention efforts should focus on patients with socioeconomic barriers and those with high LN chronicity index at LN diagnosis to improve outcomes in LN.

Supporting image 1

Figure 1. Kaplan Meier Curve shows: Panel A. CKD progression defined as kidney function impairment with sustained decrease in eGFR by 30% and eGFR <90 (CKD stage ≥2); Panel B. ESKD occurrence over 12-year follow-up period after LN diagnosis.

Supporting image 2

Table 1. Cox models showing risk factors at LN diagnosis of CKD progression defined as kidney function impairment with sustained decrease in eGFR by 30% and eGFR <90 (CKD stage ≥2) (Moroni et al., Kidney360, 2022)

Supporting image 3

Table 2. Cox models showing risk factors at LN diagnosis for end-stage kidney disease (ESKD) over 12 years follow up.


Disclosures: S. Garg: None; B. Astor: None; A. Raval: None; S. Lim: None; W. Zhong: None; S. Panzer: None; B. Rovin: AstraZeneca, 2, 5, Aurinia, 2, 5, Biogen, 2, F. Hoffmann-La Roche Ltd, 2, Genentech, 2, GlaxoSmithKlein(GSK), 2, Novartis, 2; C. Bartels: Pfizer, 5.

To cite this abstract in AMA style:

Garg S, Astor B, Raval A, Lim S, Zhong W, Panzer S, Rovin B, Bartels C. Social Disparities and Pathology Markers at Lupus Nephritis Diagnosis Predict Worse Kidney Outcomes [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/social-disparities-and-pathology-markers-at-lupus-nephritis-diagnosis-predict-worse-kidney-outcomes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/social-disparities-and-pathology-markers-at-lupus-nephritis-diagnosis-predict-worse-kidney-outcomes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology